Recent News Releases
For investor-related news, see our ASX releases here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Apr 12, 2018
Seqirus partners with American Nurse Practitioner Foundation, American Pharmacists Association and Physician Assistant Foundation to drive conversation around flu prevention in adults 65 and older...
-
Mar 29, 2018
Jacques Theurillat to be proposed to Annual Shareholder Meeting for appointment to Board Marc de Garidel will not stand for re-election All other members of the Board of Directors will stand for...
-
Mar 23, 2018
23 Mar 2018 KING OF PRUSSIA, Pa. – March 23, 2018 – CSL Behring, a global biotherapeutics leader, today announced the initiation of the AEGIS-II (ApoA-I Event reducinG in Ischemic Syndromes...
-
Mar 20, 2018Global biotech leader rated at no. 42 for patient focus, innovation and sustainable growth
20 Mar 2018 KING OF PRUSSIA, Pa. – March 20, 2018 – Forbes has named global biotechnology leader CSL Limited among the world’s Top 50 employers, landing at no. 42 in the business media’s...
-
Mar 17, 2018
Vifor Pharma gives Zeria exclusive rights to develop and market Veltassa® in Japan Potential of Veltassa® further validated with expansion into Japanese market Deal expands cardio-renal network...
-
Mar 16, 2018First and only subcutaneous immunoglobulin (SCIg) approved for the treatment of CIDP based on the largest controlled clinical study in CIDP
16 Mar 2018 KING OF PRUSSIA, Pa. – March 16, 2018 – Global biotherapeutics leader CSL Behring today announced that the U.S. Food and Drug Administration (FDA) approved Hizentra® (Immune...
-
Mar 15, 2018
IN 2017 VIFOR PHARMA RECORDED A STRONG FINANCIAL PERFORMANCE DRIVEN BY ITS THREE MEDIUM-TERM STRATEGIC GROWTH-DRIVERS AND THE SUCCESSFUL DIVESTITURE OF ITS NON-CORE WHOLESALE/RETAIL PHARMACY...
-
Mar 15, 2018First and only subcutaneous immunoglobulin approved for the treatment of CIDP, based on findings from the largest controlled clinical CIDP study
15 Mar 2018 HATTERSHEIM, Germany – 15 March 2018 – Global biotherapeutics leader CSL Behring today announced that the European Commission (EC) has granted marketing authorization for...
-
Mar 15, 2018Life Sciences Pennsylvania recognized CSL Behring’s commitment to patients for its novel subcutaneous C1 esterase inhibitor, HAEGARDA®, to prevent swelling caused by the rare genetic disorder
15 Mar 2018 KING OF PRUSSIA, Pa. – March 15, 2018 – Imagine not knowing when you might experience unpredictable, severe and painful swelling without warning in different parts of your body,...
-
Mar 13, 2018- Industry’s role in ensuring access to medicine is an imperative, not an afterthought - Patient engagement is a key driver to strengthen access
13 Mar 2018 BARCELONA, SPAIN – March 13, 2018 – In a keynote address on patients’ access to medicines at the eyeforpharma Barcelona summit, CSL Chief Executive Officer and Managing Director...